Problems with the randomized discontinuation design [7]

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4669-4670

  Sonpavde, Guru ^a   Hutson, Thomas E ^a   Galsky, Matthew D ^a   Berry, William R ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HUMAN; KIDNEY CARCINOMA; LETTER; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUMOR VOLUME; DRUG ADMINISTRATION; KIDNEY TUMOR; METHODOLOGY; NOTE; STATISTICAL ANALYSIS; SURVIVAL;

BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750600001     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.4277     Document Type: Letter

References (2)

1. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
2. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999